Recent Finacing
Recent Raise
Bryn Pharma develops and clinically advances BRYN-NDS1C, a portable, needle-free, two-dose intranasal epinephrine device for treating anaphylaxis, conducting human trials and pursuing regulatory approval.
Focus Areas
Total Raised
Funding rounds
See the team members at Bryn Pharma.
